Depot Buprenorphine Injection in the Management of Opioid Use Disorder: From Development to Implementation [Corrigendum]

Abstract

Ling W, Shoptaw S, Goodman-Meza D. Subst Abuse Rehabil. 2019;10:69–78.The authors of this paper have advised that Table 1 is incorrect. The authors advised that they had listed values for Cmax and Ctrough after a single dose of Brixadi (CAM2038) and not steady state, as it was provided for Sublocade. The new Table 1 reflects the Brixadi steady state concentrations for a more direct comparison with Sublocade.Read the original article

Keywords

• opioid use disorder
• injectable buprenorphine
• treatment barriers
• stakeholders.